Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | The role of bispecific antibodies in the treatment of R/R large B-cell lymphoma

Michael Dickinson • 30 Sep 2022
SOHO 2022
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies CAR-T

Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, Peter MacCallum Cancer Centre, Melbourne, Australia, shares some insights into the role of bispecific antibodies for the treatment of relapsed/refractory large B-cell lymphoma (R/R LBCL). This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Michael Dickinson

4:18
Pembrolizumab monotherapy for older/ABVD-ineligible patients with Hodgkin lymphoma
Michael Dickinson • 16 Jun 2023
3:48
COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in high-risk DLBCL
Michael Dickinson • 16 Jun 2023
10:25
Key highlights in NHL: updates in MCL, the role of transplantation, and novel bispecific antibodies
Michael Dickinson et al. • 12 Dec 2022
3:49
The challenges in developing bispecific antibodies for non-Hodgkin lymphoma
Michael Dickinson • 30 Sep 2022

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals